Previous Article | Next Article 
Journal of Virology, November 1998, p. 8525-8531, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Herpes Simplex Virus 1 Regulatory Protein ICP22 Interacts with a
New Cell Cycle-Regulated Factor and Accumulates in a Cell
Cycle-Dependent Fashion in Infected Cells
Renato
Bruni and
Bernard
Roizman*
The Marjorie B. Kovler Viral Oncology
Laboratories, The University of Chicago, Chicago, Illinois 60637
Received 25 May 1998/Accepted 7 July 1998
 |
ABSTRACT |
The herpes simplex virus 1 infected cell protein 22 (ICP22), the
product of the
22 gene, is a nucleotidylylated and
phosphorylated nuclear protein with properties of a transcriptional
factor required for the expression of a subset of viral genes. Here, we
report the following. (i) ICP22 interacts with a previously unknown
cellular factor designated p78 in the yeast two-hybrid system. The p78 cDNA encodes a polypeptide with a distribution of leucines reminiscent of a leucine zipper. (ii) In uninfected and infected cells, antibody to
p78 reacts with two major bands with an apparent
Mr of 78,000 and two minor bands with apparent
Mrs of 62,000 and 55,000. (ii) p78 also
interacts with ICP22 in vitro. (iii) In uninfected cells, p78 was
dispersed largely in the nucleoplasm in HeLa cells and in the
nucleoplasm and cytoplasm in HEp-2 cells. After infection, p78 formed
large dense bodies which did not colocalize with the viral regulatory
protein ICP0. (iv) Accumulation of p78 was cell cycle dependent, being
highest very early in S phase. (v) The accumulation of ICP22 in
synchronized cells was highest in early S phase, in contrast
to the accumulation of another protein, ICP27, which was relatively
independent of the cell cycle. (vi) In the course of the cell cycle,
ICP22 was transiently modified in an aberrant fashion, and this
modification coincided with expression of p78. The results suggest that
ICP22 interacts with and may be stabilized by cell cycle-dependent
proteins.
 |
INTRODUCTION |
The herpes simplex virus 1 (HSV-1)
genome encodes at least 84 different proteins whose synthesis is
coordinately regulated and sequentially ordered in a cascade fashion
(15, 16). The first group of genes to be expressed are the
genes. The expression of
genes does not require de novo protein
synthesis, whereas the expression of
and
genes expressed later
in infection requires functional
proteins. With one exception, that
of the
47 gene, the
proteins regulate viral gene expression (for
reviews, see references 34 and
35). The product of the
47 gene has been reported
to interfere with the presentation of antigenic peptides (40). The focus of this report is on the
22 gene. The
domain of the
22 gene encodes two transcripts. The transcript
traversing the entire open reading frame (ORF) encodes a 420-amino-acid
protein designated infected cell protein 22 (ICP22)
(14-16). A smaller transcript originating in the domain of
the gene, designated US1.5, directs the synthesis of a
protein containing the carboxyl-terminal 273 amino acids of ICP22
(8). Although in this report we shall trace the expression
of ICP22, we are not able to separate the function of ICP22 from that
of the US1.5 protein.
The
22 gene is dispensable for viral replication in some cells but
not others. In primary human cells and in continuous cell lines of
rodent derivation, a recombinant virus (R325) lacking the
carboxyl-terminal amino acids replicates poorly and is relatively avirulent in experimental animal systems (24, 29, 38).
Subsequent studies from this laboratory have suggested that ICP22 may
be a transcriptional factor. Thus, Purves et al. have shown that in
cells requiring the
22 gene for efficient viral replication, there
was a decrease in steady-state levels of mRNA of the
0 gene and of a
subset of late genes (e.g., US11) and, concurrently, a
decrease in the accumulation of proteins encoded by these genes (31). In still more recent studies, ICP22 was shown to be
required for the utilization of one of the four splice acceptor sites
of intron 1 of the
0 gene (9). The role of ICP22 in late
gene expression became apparent from studies showing that concurrent with the onset of viral DNA synthesis, ICP22 and ICP4, the major regulatory protein, aggregate in nuclear structures with nascent viral
DNA, RNA polymerase II, and other proteins and that this aggregation is
essential for late gene expression (22). ICP22 has also been
reported to be responsible for the aberrant phosphorylation of the
large-subunit carboxyl-terminal domain of RNA polymerase II upon HSV-1
infection (32, 33).
ICP22 undergoes extensive posttranslational modifications. These
include phosphorylation by viral protein kinases encoded by
US3 and UL13, and nucleotidylylation by casein
kinase II (5, 25, 26, 30, 31). A virus deleted in the
UL13 gene is phenotypically similar to R325, suggesting
that phosphorylation is necessary for at least some functions of ICP22
(31). Indeed, in cells infected with mutants from which
UL13 had been deleted, ICP22 fails to aggregate in the
nuclear structures containing nascent DNA, ICP4, RNA polymerase II, and
other factors (22).
In this report, we show that (i) ICP22 interacts with a hitherto
unidentified cellular protein designated p78, (ii) p78 synthesis is
cell cycle dependent, since the protein is detected only early in the S
phase, (iii) the accumulation of ICP22, but not of ICP27, in cells
infected with wild-type virus strongly depends on the phase of the cell
cycle at the time of infection, with the highest expression of ICP22
occurring during S phase, and (iv) ICP22 made in early S phase is
transiently modified in a fashion different from that of the
corresponding protein accumulating later in the cell cycle or in
asynchronized cells.
These results suggest that p78 may be a regulator of ICP22 expression
and that ICP22 is capable of interacting with cell cycle-regulated proteins.
 |
MATERIALS AND METHODS |
Cell lines and viruses.
HeLa and HEp-2 cell lines were
obtained from the American Type Culture Collection. The human
143TK
cell line was obtained from Carlo Croce. A strain
of human foreskin fibroblasts (HFF) was the gift of George Kemble
(Aviron Inc., Mountainview Calif.). HSV-1(F) is the prototype HSV-1
strain used in this laboratory (11). Recombinant virus R7353
is deleted for the UL13 and US3 genes and has
been described previously (31).
Plasmids.
pRB4965 was constructed by ligating the 1.5-kb
HeLa cDNA encoding the carboxyl-terminal 370 amino acids of p78 as an
EcoRI/XhoI fragment in frame with the glutathione
S-transferase (GST) gene in pGEX4T-3 (Pharmacia). The
GST-ORF P recombinant pRB4966 has been described elsewhere
(7). pRB5113 contains the entire coding sequence of the
22/US1.5
genes fused in frame with the DNA-binding domain of GAL4 in pGBT9 (Clontech).
Yeast two-hybrid system and isolation of cDNA clones.
pRB5113 was transformed into yeast strain HF7c (Clontech).
Transformants were grown to large scale and transformed with a HeLa
cDNA library cloned in pGADGH (Clontech) or a cDNA library derived from
an Epstein-Barr virus-immortalized human peripheral blood B-lymphocyte
cell line (Clontech). Positive clones encoding interacting polypeptides
were selected and isolated as described previously (7). cDNA
clones relevant to these studies were isolated by hybridization of a
HeLa S3 cDNA library cloned into
gt11 (human HeLa S3 5'-STRETCH PLUS
cDNA library; Clontech) with the 1.5-kb HeLa cDNA isolated from the
two-hybrid screen as a probe. Seven positive clones were isolated and
shown to contain inserts ranging from 0.5 to 2.6 kbp. The
largest insert was subcloned into pGEM3Zf(
) (Promega,
Madison, Wis.) and sequenced on both strands.
Preparation of cell extracts.
HeLa cell extract for GST
affinity precipitation was prepared as follows. Subconfluent HeLa cells
grown in a 150-cm2 flask were infected with 10 PFU of
HSV-1(F) per cell. After incubation for 18 h at 37°C, the
infected cells were scraped into phosphate-buffered saline (PBS),
washed once with PBS, and resuspended in 600 µl of PBS* (1%
deoxycholate-1% Nonidet P-40-10 M tolylsulfonyl phenylalanyl chloromethyl ketone-10 M
-tosyl-L-lysine chloromethyl
ketone in PBS). Binding reactions were done with 150 to 200 µl of
cell extract. For electrophoretic separation of proteins in denaturing gels, cells from 25 and 150-cm2 flasks were scraped into
PBS, rinsed with PBS, and resuspended in 200 and 500 µl,
respectively, of 2× disruption buffer (100 mM Tris-HCl [pH 6.8], 200 mM dithiothreitol, 4% sodium dodecyl sulfate, 0.2% bromphenol blue,
20% glycerol).
Antibodies.
Monoclonal antibodies to ICP0 and ICP27,
purchased from the Goodwin Institute, Plantation, Fla., and the
polyclonal antiserum R77 to ICP22 have been described elsewhere
(1, 2). Monoclonal antibody to coilin protein was obtained
from Maria Carmo-Fonseca, University of Lisbon, Lisbon, Portugal. The
polyclonal serum to p78 was generated as follows. Escherichia
coli BL21 was transformed with pRB4965, and the fusion protein
encoded by the plasmid was purified from a large-scale culture as
recommended by the manufacturer (Pharmacia). Two rabbits were injected
at Josman Laboratories (Napa, Calif.) subcutaneously with 0.3 to 0.5 mg
of fusion protein each time at 14-day intervals. The serum used in the
studies reported here was collected 1 week after the fourth
immunization.
Immunoblots.
Cell extracts were separated in sodium dodecyl
sulfate-7% denaturing polyacrylamide gels as described by Sambrook et
al. (36). Proteins were then electrically transferred to
nitrocellulose sheets (Bio-Rad), blocked for 1 h in 5% milk (in
PBS) at room temperature, and then reacted for 2 h at room
temperature with the primary antibody diluted in 1% bovine serum
albumin (BSA) (in PBS). Monoclonal antibodies to ICP27 and polyclonal
antibody to ICP22 were diluted 1:500, whereas the p78 antiserum was
diluted 1:1,500. The immunoblots were rinsed four times with 5% milk, reacted for 1 h at room temperature with goat anti-rabbit or goat anti-mouse antibody conjugated to alkaline phosphatase diluted 1:3,000
in 5% milk, and rinsed once with 5% milk and four times with PBS.
Colorimetric reactions were done as recommended by the manufacturer
(Bio-Rad).
Immunofluorescence.
Cells grown in wells on 1- by 3-in.
slides were infected with 106 PFU of HSV-1(F). After
incubation at 37°C, the cells were fixed in methanol for 20 min at
20°C, reacted for 30 to 60 min in PBS containing 20% normal human
serum and 1% BSA at room temperature, rinsed once with PBS, and then
reacted for 18 to 24 h at 4°C with the primary antibodies
diluted in PBS containing 10% normal human serum and 1% BSA.
Dilutions were 1:300 for the p78 antiserum and 1:200 for the ICP0
antibody. The cells were then washed three times with PBS, reacted for
1 h at room temperature with goat anti-rabbit immunoglobulin G
(IgG) conjugated to fluorescein isothiocyanate (FITC; Sigma) and goat
anti-mouse IgG conjugated to Texas red (Molecular Probes), rinsed again
three times with PBS, and mounted in PBS containing 90% glycerol and 1 mg of p-phenylenediamine per ml. The slides were examined
with a Zeiss confocal fluorescence microscope, and digitized images
were acquired with software provided with the microscope and printed by
a Tektronix 440 phaser printer. Single-color images were acquired by
excitation using an argon-krypton laser at 488 nm (FITC) or 568 nm
(Texas red). Double-stained images were acquired by a split image of
both fluorochromes filtered by a 515- to 540-nm band pass (FITC) and
590 nm long-pass (Texas red) filters and subsequent overlay of the
two-color images.
Synchronization of HeLa cells.
HeLa cells were blocked in
early S phase as described by Johnson et al. (18). HeLa
cells (106 cells per 25-cm2 flask) were
incubated in medium supplemented with 2 mM thymidine for 24 to 25 h at 37°C, washed twice in regular medium, and incubated for 12 to
14 h in regular medium. Cells were then incubated again in medium
containing 2 mM thymidine for another 24 h and released from the
block by rinsing the cells twice in regular medium.
 |
RESULTS |
ICP22 interacts with a previously unidentified cellular
factor.
In this series of experiments, we screened a HeLa cDNA
library cloned in the two-hybrid system vector pGADGH for cellular gene
products interacting with ICP22, using the entire
22 gene as bait.
Approximately 2 × 106 yeast colonies were screened,
and three clones were shown to specifically interact with ICP22 in the
yeast two-hybrid systems when assayed in a
-galactosidase assay. The
three clones contained the same 1.5-kb insert, as shown by restriction
enzyme digestion and partial DNA sequencing (data not shown). A clone
containing the same sequence was found in a screen using a cDNA library
derived from an Epstein-Barr virus-immortalized human peripheral blood B-lymphocyte cell line (Clontech). One insert was sequenced completely on both strands of the DNA and found to contain a 370-codon ORF. A HeLa
cDNA library was screened with the original 1.5-kb insert as a probe,
and several clones were isolated. The largest clone contained an insert
of approximately 2.6 kb. Sequencing of this clone revealed an ORF of
534 codons preceded by a 500-bp 5' untranslated sequence (Fig.
1). The ORF in the 1.5-kb insert
corresponds to the 3' domain of the 534 codon ORF in the 2.6-kb cDNA.
We conclude that ICP22 interacts with the carboxyl-terminal 370 amino
acids of the protein encoded by the 2.6-kb DNA.

View larger version (54K):
[in this window]
[in a new window]

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 1.
Nucleotide and amino acid sequences of p78. The amino
acid sequence is shown below the DNA sequence. The underlined sequence
refers to the putative leucine zipper region. Hydrophobic residues
occurring every seven amino acids are circled. The boxed amino acid
sequences are potential nuclear localization signals. Numbers on the
right refer to the DNA sequence.
|
|
No significant homologies to any known DNA or amino acid sequence were
detected by either the FastA or BLAST computer program
(
3,
27). The protein was designated p78 since an antiserum
raised
against a bacterial fusion protein containing the original
370 amino
acids reacted with two major polypeptide bands with
an apparent
Mr of 78,000 in an immunoblot (see Materials and
Methods
and below). The predicted amino acid sequence of p78 (Fig.
1)
contained a stretch of hydrophobic residues (leucines and methionines)
between amino acid residues 152 and 201, reminiscent of a leucine
zipper (
4,
17).
GST-p78 chimeric protein binds ICP22 from infected cell
lysates.
To verify the results of the two-hybrid-system assays, we
constructed a fusion protein consisting of GST fused in frame with the
370 codons contained in the original 1.5-kbp cDNA insert and shown to
react with ICP22 in the two-hybrid system. The chimeric protein GST-p78
was induced and purified from bacterial cultures and then reacted with
HSV-infected HeLa cell extract as described in Materials and Methods.
As shown in Fig. 2, the GST-p78 chimeric protein bound native ICP22, whereas GST alone or an irrelevant GST
fusion protein did not. The GST-p78 chimeric protein did not bind any
of the other
proteins, ICP0, ICP4, and ICP27 (data not shown).
Interestingly, of the four ICP22 bands prominent in infected HeLa cell
extract, the second-fastest-migrating band was the most intense in the
GST pull-down experiment even though it was not the most abundant ICP22
isoform in the infected cell extract (compare lanes 2 and 4 in Fig. 2).
These results suggest that p78 has a higher affinity for this isoform
of ICP22 than for the other ones. This band most likely represents an
ICP22 posttranslationally modified differently from the ICP22 isoforms forming the other bands (2, 30).

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 2.
Photographic image of cell proteins bound to GST fusion
proteins, electrophoretically separated in denaturing gels and reacted
with a serum to ICP22. Recombinant pGEX vectors were grown in E. coli BL21, and fusion proteins were isolated as recommended by the
manufacturer (Pharmacia). Fusion protein (2 to 5 µg) was mixed with
HSV-1(F)-infected HeLa extract and incubated at 4°C for 2 to 4 h. Beads were collected by centrifugation, washed three times with PBS*
(see Materials and Methods), and resuspended in 60 µl of 2×
disruption buffer. Proteins were separated in 7% denaturing
polyacrylamide gel, transferred to nitrocellulose, blocked, reacted
with R77 and then with a goat anti-rabbit antibody conjugated to
alkaline phosphatase, and processed as described by the manufacturer
(Bio-Rad). Lanes 1 to 3, HeLa cell extract bound to GST, GST-p78, and
GST-ORF P, respectively; lane 4, cell extract from infected HeLa
cells.
|
|
Accumulation of the p78-related protein is cell cycle
dependent.
To determine the properties of the native eukaryotic
cell protein, a polyclonal rabbit antiserum was raised against the
GST-p78 chimeric protein as described in Materials and Methods. In the first series of experiments, uninfected HeLa cell extract was assayed
for the presence of p78 by immunoblotting. The p78 antiserum reacted
with four protein bands, whereas the preimmune serum did not react at
all (Fig. 3). The doublet containing most
of the protein had an apparent Mr of
approximately 78,000, whereas the two other bands had apparent
Mrs of 62,000 and 55,000. At present it is not
clear whether the two minor bands represent the native protein, the
degradation products of the high-molecular-weight form, or, for
example, products of alternatively spliced mRNAs. Intriguingly, an in
vitro transcription-translation reaction of the 2.6-kb cDNA described
above yielded a polypeptide with an apparent Mr
of approximately 55,000 (data not shown), well within the expected
range for an ORF encoding a protein of 534 amino acids. These results
suggest that p78 represented a highly modified polypeptide. It should
be stressed that this pattern was very reproducible from one experiment
to another and was also characteristic of lysates of infected HEp-2
cells, 143TK
cells, or HFF (see below and data not
shown).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3.
Photographic image of HeLa cell proteins,
electrophoretically separated in denaturing gels and reacted with a
preimmune serum (lane 1) or with a serum to p78 (lane 2). Uninfected
HeLa cell extract was separated in a 10% denaturing polyacrylamide
gel, blocked, reacted with a rabbit preimmune serum or serum to p78
(see Materials and Methods) and then with a goat anti-rabbit antibody
conjugated to alkaline phosphatase, and processed as described by the
manufacturer (Bio-Rad). The major p78 band resolves as a doublet in
lower-percentage polyacrylamide gels.
|
|
The purpose of the second series of experiments was to localize by
immunofluorescence the cellular compartment in which the
native p78
protein accumulated in infected and uninfected cells.
The results were
as follows (Fig.
4). (i) Only a small
fraction
of total cells reacted with the anti-p78 antibody (Fig.
4).
(ii)
The localization varied depending on the cell line. The protein
localized primarily in the nuclei of HeLa cells and in both the
nuclei
and cytoplasm of HEp-2 cells (Fig.
4). (iii) In infected
HEp-2 cells,
p78 was localized in a few dense bodies in the nucleus
or at the
nuclear membrane. However, these structures did not
colocalize with the
regulatory protein ICP0 at early or late times
after infection (Fig.
4)
or with the coilin protein (data not
shown).

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 4.
Photomicrographs of uninfected (A and B) and
HSV-1(F)-infected (C to E and F to H) HeLa cells (B) and Hep-2 cells
(A, C to E, and F to H) reacted with an antibodies to p78 and ICP0 (see
Materials and Methods). Infected cells were fixed at 3 h after
infection (C to E) or at 18 h after infection (F to H).
Immunofluorescence was done as described in Materials and Methods. (A,
B, C, and F) FITC-labeled anti-rabbit IgG antibody to p78 antiserum; (D
and G) Texas red-labeled anti-mouse IgG to the ICP0 antibody; (E and H)
overlays of panels C and D and panels F and G, respectively.
|
|
The observation that only a fraction of the cells contained detectable
amounts of p78 related, native protein raised the possibility
that the
expression of the p78 protein was cell cycle dependent.
To test this
hypothesis, two sets of experiments were done. In
the first, HFF were
harvested at a cell confluency of approximately
50%, or after they
were fully confluent and contact inhibited,
and the presence of
p78 was then assayed by immunoblotting. As
shown in Fig.
5A, p78 was present in dividing HFF cells
(lane
1), but could not be detected in non-dividing cells (lane 2).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 5.
Photographic images of uninfected HFF and HeLa cell
extracts, electrophoretically separated in denaturing gels and reacted
with a serum to p78. (A) HFF extracts were prepared at 50% cell
confluency (lane 1) and at 100% cell confluency (lane 2), separated in
7% denaturing gels, transferred to nitrocellulose, blocked, and
reacted with a serum to p78 and then with a goat anti-rabbit antibody
conjugated to alkaline phosphatase. Gel loading was monitored by
staining for actin (not shown). (B) HeLa cell extracts were prepared
from unsynchronized cells (leftmost lane) and from synchronized cells
at 0, 0.5, 1, 3, and 7 h after release from block (see Materials
and Methods) and processed as described above.
|
|
In a second set of experiments, HeLa cells were blocked at the
G
1/S interphase as described in Materials and Methods,
harvested
at different time intervals after release from the block,
solubilized,
subjected to electrophoresis in denaturing polyacrylamide
gels,
transferred to a nitrocellulose sheet, and probed with the
anti-p78
antibody. As shown in Fig.
5B, p78 accumulation was highest at
0.5 h after release from the block. Thus, p78 levels were highest
very early in S phase but undetectable in G
2, i.e., at
7 h after
release from the block.
ICP22 accumulates preferentially in cells infected during early S
phase.
The results described above suggested that the functions of
ICP22 may be cell cycle dependent. To determine whether expression of
ICP22 was affected by the phase of the cell cycle in which viral gene
expression was initiated, HeLa cells were blocked at the
G1/S boundary as described above and infected with
wild-type HSV-1 at 0, 0.5, 1, 4, or 8 h after release from the
block. Cells were harvested 24 h after infection, solubilized,
subjected to electrophoresis in denaturing gels, and reacted with
antibody to ICP22 and ICP27. The results were as follows. ICP22 levels were highest in cells infected at 0.5 or 1 h after release from the block, but the protein was almost undetectable in cells infected at
7 h (Fig. 6). In contrast,
accumulation of ICP27 was not at all or only slightly affected by the
phase of the cell cycle at the time of infection. Inasmuch as the
patterns of expression of ICP22 and p78 almost overlap (compare Fig. 5
and 6), these results suggest that the accumulation of ICP22 and of p78
may be determined by similar cell cycle-regulated factors.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 6.
Photographic image of wild-type virus-infected HeLa cell
extracts, separated in denaturing gels and reacted with sera to viral
proteins. Unsynchronized HeLa cells (leftmost lane) and
synchronized HeLa cells were infected with HSV-1(F) at the time points
shown after release from block (see Materials and Methods) for 24 h. Cell extracts were separated in 7% denaturing polyacrylamide gels,
transferred to nitrocellulose sheets, blocked, reacted with sera to
ICP22 and ICP27 and then with a goat anti-mouse (ICP27) or a goat
anti-rabbit (for ICP22) antibody conjugated to alkaline phosphatase,
and processed as recommended by the manufacturer.
|
|
ICP22 made early in S phase is posttranslationally modified
differently from that made in asynchronously dividing HeLa cells.
The results described above indicate that the accumulation of ICP22
depended on the phase of the cell cycle at the time of infection and
that the highest accumulation occurred in cells infected very early in
the S phase. To further investigate this observation, HeLa cells were
synchronized as described above and infected with HSV-1(F) 0.5 h
after release from the block. The cells were harvested at 2-h intervals
after infection, and extracts were prepared and processed for
immunoblotting as described in Materials and Methods. As shown in Fig.
7, lane 1, infected synchronized HeLa
cells yielded at 2 h after infection novel, hitherto undetected forms of ICP22 in addition to posttranslationally processed forms common to productive infection (lanes 2 to 5) and described earlier (30, 31). This novel modification of ICP22 coincided with expression of p78 (lane 1). This modification was not dependent on the
expression of the viral protein kinases encoded by UL13 and
US3, respectively, inasmuch as infection of synchronized
HeLa cells with the recombinant virus R7353 lacking both
UL13 and US3 yielded identical novel forms of
ICP22, although at later times after infection than in cells infected
with wild-type virus (lanes 6 to 10). As in the case of cells infected
with the wild-type virus HSV-1(F), however, the accumulation of this
novel form of ICP22 coincided with expression of p78 (lanes 8 and 9).

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 7.
Photographic image of cell extracts infected with
wild-type virus or with recombinant R7353, separated in denaturing gels
and reacted with sera to ICP22 and p78. Synchronized HeLa cells were
infected at 0.5 h after release from block with either HSV-1(F)
(lanes 1 to 5) or recombinant R7353 (lanes 6 to 10), and extracts were
prepared at the times indicated after infection. Cell extracts were
separated in duplicate 7% denaturing polyacrylamide gels, transferred
to nitrocellulose sheets, and reacted with sera to ICP22 (upper panel)
and p78 (lower panel).
|
|
 |
DISCUSSION |
The salient features of this report are as follows. (i) We have
identified p78, a previously unknown cellular protein that interacts
with ICP22 in the yeast two-hybrid system and in in vitro assays.
Although p78 does not have significant homology to other known proteins
or nucleotide sequences, it contains a leucine zipper-like region. The
protein sequence of p78 also contains several stretches of basic
residues which could act as nuclear localization signals (Fig. 1; see
reference 10 for a review). These features of p78
are characteristic of regulatory proteins (17). The
hypothesis that p78 is a regulatory protein which interacts with ICP22
is tantalizing inasmuch as ICP22 has obvious regulatory functions but
lacks features characteristic of regulatory proteins such as
DNA-binding domains, Zn-binding domains, or ability to transactivate
gene expression. This situation is reminiscent of the one described for
TIF (VP16) and for the Epstein-Barr virus transactivator EBNA-2
(23). In the latter case, it has been shown that EBNA-2 is
targeted to the DNA by a cellular enhancer-binding protein
(23). Interestingly, HSV-1 ICP22 and homologs of other alphaherpeviruses share conserved amino acid sequences in their carboxyl-terminal domains that are rich in acidic residues
(39). This region could potentially act as a transactivating
domain.
(ii) Both p78 and ICP22 are regulated in cell cycle-dependent manner.
Evidence in support of this conclusion stems from three observations.
First, ICP22 accumulates optimally in cells during the first several
hours after release from the G1/S interphase. Surprisingly,
ICP27 but not ICP22 was detected in cells infected 7 h after the
release and harvested 24 h later. Inasmuch as most asynchronous
cells infected at appropriate multiplicity contain ICP22 as detected by
immunofluorescence, we hypothesize that ICP22 was made and degraded
faster in cells infected in G2 than in cells infected
during G1 or S phase. This was the most surprising and unexpected observation made in this study, and it suggests that ICP22
is stabilized by a factor available during G1 or S phase but not later.
Second, ICP22 made during the first few hours after release from block,
and infection with wild-type virus was posttranslationally processed
differently from that made in the majority of infected cells dividing
asynchronously and infected at stages other than at the
G1/S interphase. This form disappears later in infection and is therefore either reprocessed or degraded.
Third, p78 accumulated and was detectable only in lysates of cells in
early S phase. The interdependence of p78 and ICP22 on the cell cycle
phase was particularly apparent in the experiment with
UL13/
US3 recombinant virus. In that
experiment, the accumulation of both ICP22 and of p78 was delayed by
several hours. Both the modified form of ICP22 and p78 accumulated at
the same time after release from block and infection. Although the
observation that in cells infected with this recombinant both proteins
appeared after several hours of delay was reproducible, it may not be
significant since we have observed a delay in the maximal accumulation
of both proteins in one experiment involving infection of cells
released from block with the wild-type, parental virus. Except for the delay in accumulation of ICP22 and of p78, the results do not support a
role for the viral protein kinases UL13 and US3
in the novel processing of ICP22 observed in this study.
A central question is the role of the interaction of ICP22 and
p78. The evidence presented in Fig. 2 is that p78 binds all forms of
ICP22 but appears to prefer one form, and therefore the two proteins
could be expected to interact in the infected cells. The function of
the interaction is not known. It should be noted, however, that there
is increasing evidence that herpesvirus proteins interact with cellular
proteins to either block cellular proteins or stabilize their function.
For example, among
proteins, it has been reported that
47 binds
to TAP1/TAP2 to block the transport of antigenic peptides to the
surface of the infected cell (40), ICP22 has been reported
to modify the phosphorylation of RNA polymerase in some infected cells
(32, 33), and ICP27 binds and sequesters components of
spliceosomes (28, 37), whereas ICP0 binds a ubiquitin-specific protease, binds to and stabilizes cyclin D3, and
binds the translation elongation factor 1 (12, 19, 20). Among proteins made later in infection, UL13 protein kinase
hyperphosphorylates elongation factor 1,
134.5 protein
binds to protein phosphatase 1
to dephosphorylate the
subunit of
eukaryotic translation initiation factor 2, and the US9
protein is ubiquitinated and is bound to proteosomes but appears to be
stable (6, 13, 21). The involvement of herpesviruses with
cell cycle progression is evident not only from the stabilization of
cyclin D3 by ICP0 but also by the observation that some herpesviruses
encode a cyclin D3 homolog. It is conceivable that other viral proteins
including ICP22 have evolved interactions with cellular proteins to
control specific aspects of the cell cycle progression.
Nucleotide sequence accession number. The accession number
for p78 is AF068007.
 |
ACKNOWLEDGMENTS |
We thank Patricia L. Ward for assistance with confocal
microscopy.
This study was aided by PHS grant CA47451 from the National Cancer
Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The Marjorie B. Kovler Viral Oncology Laboratories, The University of Chicago, 910 E. 58th St., Chicago, IL 60637. Phone: (773) 702-1898. Fax: (773) 702-1631. E-mail: bernard{at}cummings.uchicago.edu.
 |
REFERENCES |
| 1.
|
Ackermann, M.,
D. K. Braun,
L. Pereira, and B. Roizman.
1984.
Characterization of herpes simplex virus 1 proteins 0, 4, and 27 with monoclonal antibodies.
J. Virol.
52:108-118[Abstract/Free Full Text].
|
| 2.
|
Ackermann, M.,
M. Sarmiento, and B. Roizman.
1985.
Application of antibody to synthetic peptides for characterization of the intact and truncated 22 protein specified by herpes simplex 1 and the R325 22 deletion mutant.
J. Virol.
56:207-215[Abstract/Free Full Text].
|
| 3.
|
Altschul, S. F.,
W. Gish,
W. Miller,
E. W. Myers, and D. J. Lipman.
1990.
Basic local alignment search tool.
J. Mol. Biol.
215:403-410[Medline].
|
| 4.
|
Baxevanis, A. D., and C. R. Vinson.
1993.
Interactions of coiled coils in transcription factors: where is the specificity?
Curr. Opin. Genet. Dev.
3:278-285[Medline].
|
| 5.
|
Blaho, J. A.,
C. Mitchell, and B. Roizman.
1993.
Guanylylation and adenylylation of the regulatory proteins of the herpes simplex virus require a viral or function.
J. Virol.
67:3891-3900[Abstract/Free Full Text].
|
| 6.
|
Brandimarti, R., and B. Roizman.
1997.
US9, a stable lysine-less herpes simplex virus 1 protein, is ubiquitinated before packaging into virions and associates with proteasomes.
Proc. Natl. Acad. Sci. USA
94:13973-13978[Abstract/Free Full Text].
|
| 7.
|
Bruni, R., and B. Roizman.
1996.
Open reading frame P a herpes simplex virus gene repressed during productive infection encodes a protein that binds a splicing factor and reduces synthesis of viral proteins made from spliced mRNA.
Proc. Natl. Acad. Sci. USA
93:10423-10427[Abstract/Free Full Text].
|
| 8.
|
Carter, K. I., and B. Roizman.
1996.
The promoter and transcriptional unit of a novel herpes simplex virus 1 gene are contained in, and encode a protein in frame with, the open reading frame of the 22 gene.
J. Virol.
70:172-178[Abstract].
|
| 9.
|
Carter, K. L., and B. Roizman.
1996.
Alternatively spliced mRNAs predicted to yield frame-shift proteins and stable intron 1 RNAs of the herpes simplex virus 1 regulatory gene 0 accumulate in the cytoplasm of infected cells.
Proc. Natl. Acad. Sci. USA
93:12535-12540[Abstract/Free Full Text].
|
| 10.
|
Dingwall, C., and R. A. Laskey.
1991.
Nuclear targeting sequences a consensus?
Trends Biochem. Sci.
16:478-481[Medline].
|
| 11.
|
Ejercito, P. M.,
E. D. Kieff, and B. Roizman.
1968.
Characterization of herpes simplex virus strains differing in their effects on social behavior of infected cells.
J. Gen. Virol.
2:357-364[Abstract/Free Full Text].
|
| 12.
|
Everett, R. D.,
M. Meredith,
A. Orr,
A. Cross,
M. Kathoria, and J. Parkinson.
1997.
A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein.
EMBO J.
16:566-577[Medline].
|
| 13.
|
He, B.,
M. Gross, and B. Roizman.
1997.
The 134.5 protein of herpes simplex virus 1 complexes with protein phosphatase to dephosphorylate the subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.
Proc. Natl. Acad. Sci. USA
94:843-848[Abstract/Free Full Text].
|
| 14.
|
Honess, R. W., and B. Roizman.
1973.
Proteins specified by herpes simplex virus. XI. Identification and relative molar rates of synthesis of structural and nonstructural herpes virus polypeptides in the infected cell.
J. Virol.
12:1347-1365[Abstract/Free Full Text].
|
| 15.
|
Honess, R. W., and B. Roizman.
1974.
Regulation of herpes simplex virus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins.
J. Virol.
14:8-19[Abstract/Free Full Text].
|
| 16.
|
Honess, R. W., and B. Roizman.
1975.
Regulation of herpes simplex virus macromolecular synthesis: sequential transition of polypeptide synthesis requires functional viral polypeptides.
Proc. Natl. Acad. Sci. USA
72:1276-1280[Abstract/Free Full Text].
|
| 17.
|
Hurst, H. C.
1994.
Sequences of bZIP proteins.
Prot. Prof.
1:125-134.
|
| 18.
|
Johnson, R. T.,
C. S. Downes, and R. E. Meyn.
1993.
The synchronization of mammalian cells, p. 1-24.
In
P. Fantes, and R. Brooks (ed.), The cell cycle. A practical approach. IRL Press, Oxford, England.
|
| 19.
|
Kawaguchi, Y.,
R. Bruni, and B. Roizman.
1997.
Interaction of herpes simplex virus 1 regulatory protein ICP0 with elongation factor 1 :ICP0 affects translational machinery.
J. Virol.
71:1019-1024[Abstract].
|
| 20.
|
Kawaguchi, Y.,
C. Van Sant, and B. Roizman.
1997.
Herpes simplex virus 1 regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3.
J. Virol.
71:7328-7336[Abstract].
|
| 21.
|
Kawaguchi, Y.,
C. Van Sant, and B. Roizman.
1998.
Eukaryotic elongation factor 1 is hyperphosphorylated by the protein kinase encoded by the UL13 gene of herpes simplex virus 1.
J. Virol.
72:1731-1736[Abstract/Free Full Text].
|
| 22.
|
Leopardi, R.,
P. L. Ward,
W. O. Ogle, and B. Roizman.
1997.
Association of herpes simplex virus regulatory protein ICP22 with transcriptional complexes EAP, ICP4, RNA polymerase II, and viral DNA requires posttranslational modification by the UL13 protein kinase.
J. Virol.
71:1133-1139[Abstract].
|
| 23.
|
Ling, P. D.,
D. R. Rawlins, and S. D. Hayward.
1993.
The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein.
Proc. Natl. Acad. Sci. USA
90:9237-9241[Abstract/Free Full Text].
|
| 24.
|
Meignier, B.,
R. Longnecker,
P. Mavromara-Nazos,
A. E. Sears, and B. Roizman.
1988.
Virulence of and establishment of latency by genetically engineered mutants of herpes simplex virus 1.
Virology
162:251-254[Medline].
|
| 25.
|
Mitchell, C.,
J. A. Blaho, and B. Roizman.
1994.
Casein kinase II specifically nucleotidylylates in vitro the amino acid sequence of the protein encoded by the 22 gene of herpes simplex virus 1.
Proc. Natl. Acad. Sci. USA
91:11864-11868[Abstract/Free Full Text].
|
| 26.
|
Mitchell, C.,
J. A. Blaho,
A. L. McCormick, and B. Roizman.
1997.
The nucleotidylylation of herpes simplex virus 1 regulatory protein 22 by human casein kinase II.
J. Biol. Chem.
272:25394-25400[Abstract/Free Full Text].
|
| 27.
|
Pearson, W. R., and D. J. Lipman.
1988.
Improved tools for biological sequence comparison.
Proc. Natl. Acad. Sci. USA
85:2444-2448[Abstract/Free Full Text].
|
| 28.
|
Phelan, A.,
M. Carmo-Fonseca,
J. McLauchlan,
A. I. Lamond, and J. B. Clements.
1993.
A herpes simplex virus type 1 immediate-early gene product, IE63, regulates small nuclear ribonucleoprotein distribution.
Proc. Natl. Acad. Sci. USA
90:9056-9060[Abstract/Free Full Text].
|
| 29.
|
Post, L. E., and B. Roizman.
1981.
A generalized technique for deletion of specific genes in large genomes: gene 22 of herpes simplex virus is not essential for growth.
Cell
25:227-232[Medline].
|
| 30.
|
Purves, F. C., and B. Roizman.
1992.
The UL13 gene of the herpes simplex 1 encodes the functions for posttranslational processing associated with phosphorylation of the regulatory protein 22.
Proc. Natl. Acad. Sci. USA
89:7310-7314[Abstract/Free Full Text].
|
| 31.
|
Purves, F. C.,
W. O. Ogle, and B. Roizman.
1993.
Processing of the herpes simplex virus regulatory protein 22 mediated by the UL13 protein kinase determines the accumulation of a subset of and mRNAs and proteins in infected cells.
Proc. Natl. Acad. Sci. USA
90:6701-6705[Abstract/Free Full Text].
|
| 32.
|
Rice, S. A.,
M. C. Long,
V. Lam, and C. A. Spencer.
1994.
RNA polymerase II is aberrantly phosphorylated and localized to viral replication compartments following herpes simplex virus infection.
J. Virol.
68:988-1001[Abstract/Free Full Text].
|
| 33.
|
Rice, S. A.,
M. C. Long,
V. Lam,
P. A. Schaffer, and C. A. Spencer.
1995.
Herpes simplex virus immediate-early protein ICP22 is required for viral modification of host RNA polymerase II and establishment of the normal viral transcription program.
J. Virol.
69:5550-5559[Abstract].
|
| 34.
|
Roizman, B.
1996.
The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors.
Proc. Natl. Acad. Sci. USA
93:11307-11312[Abstract/Free Full Text].
|
| 35.
|
Roizman, B., and A. E. Sears.
1996.
Herpes simplex viruses and their replication, p. 2231-2295.
In
B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, M. S. Hirsch, J. L. Melnick, T. P. Monath, and B. Roizman (ed.), Fields virology, 3rd ed. Raven Press, New York, N.Y.
|
| 36.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 37.
|
Sandri-Goldin, R. M., and M. K. Hibbard.
1996.
The herpes simplex virus type 1 regulatory protein ICP27 coimmunoprecipitates with anti-Sm antiserum, and the C terminus appears to be required for this interaction.
J. Virol.
70:108-118[Abstract].
|
| 38.
|
Sears, A. E.,
I. W. Halliburton,
B. Meignier,
S. Silver, and B. Roizman.
1985.
Herpes simplex virus 1 mutant deleted in the 22 gene: growth and gene expression in permissive and restrictive cells and establishment of latency in mice.
J. Virol.
55:338-346[Abstract/Free Full Text].
|
| 39.
|
Schwyzer, M.,
U. V. Wirth,
B. Vogt, and C. Fraefel.
1994.
BICP22 of bovine herpesvirus 1 is encoded by a spliced 1.7 kB RNA which exhibits immediate early and late transcription kinetics.
J. Gen. Virol.
75:1703-1711[Abstract/Free Full Text].
|
| 40.
|
York, I. A.,
C. Roop,
D. W. Andrews,
S. R. Riddell,
F. L. Graham, and D. C. Johnson.
1994.
A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes.
Cell
77:525-535[Medline].
|
Journal of Virology, November 1998, p. 8525-8531, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fraser, K. A., Rice, S. A.
(2007). Herpes Simplex Virus Immediate-Early Protein ICP22 Triggers Loss of Serine 2-Phosphorylated RNA Polymerase II. J. Virol.
81: 5091-5101
[Abstract]
[Full Text]
-
Orlando, J. S., Balliet, J. W., Kushnir, A. S., Astor, T. L., Kosz-Vnenchak, M., Rice, S. A., Knipe, D. M., Schaffer, P. A.
(2006). ICP22 Is Required for Wild-Type Composition and Infectivity of Herpes Simplex Virus Type 1 Virions. J. Virol.
80: 9381-9390
[Abstract]
[Full Text]
-
Cun, W., Hong, M., Liu, L.-D., Dong, C.-H., Luo, J., Li, Q.-H.
(2006). Structural and functional characterization of herpes simplex virus 1 immediate-early protein infected-cell protein 22.. J Biochem
140: 67-73
[Abstract]
[Full Text]
-
Orlando, J. S., Astor, T. L., Rundle, S. A., Schaffer, P. A.
(2006). The Products of the Herpes Simplex Virus Type 1 Immediate-Early US1/US1.5 Genes Downregulate Levels of S-Phase-Specific Cyclins and Facilitate Virus Replication in S-Phase Vero Cells.. J. Virol.
80: 4005-4016
[Abstract]
[Full Text]
-
Shimono, K., Shimono, Y., Shimokata, K., Ishiguro, N., Takahashi, M.
(2005). Microspherule Protein 1, Mi-2{beta}, and RET Finger Protein Associate in the Nucleolus and Up-regulate Ribosomal Gene Transcription. J. Biol. Chem.
280: 39436-39447
[Abstract]
[Full Text]
-
Okumura, K., Zhao, M., DePinho, R. A., Furnari, F. B., Cavenee, W. K.
(2005). From the Cover: Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc. Natl. Acad. Sci. USA
102: 2703-2706
[Abstract]
[Full Text]
-
Sun, A., Devi-Rao, G. V., Rice, M. K., Gary, L. W., Bloom, D. C., Sandri-Goldin, R. M., Ghazal, P., Wagner, E. K.
(2004). Immediate-Early Expression of the Herpes Simplex Virus Type 1 ICP27 Transcript Is Not Critical for Efficient Replication In Vitro or In Vivo. J. Virol.
78: 10470-10478
[Abstract]
[Full Text]
-
Brandt, C. R., Kolb, A. W.
(2003). Tyrosine 116 of the Herpes Simplex Virus Type 1 IE{alpha}22 Protein Is an Ocular Virulence Determinant and Potential Phosphorylation Site. IOVS
44: 4601-4607
[Abstract]
[Full Text]
-
Brandt, C. R., Kolb, A. W., Shah, D. D., Pumfery, A. M., Kintner, R. L., Jaehnig, E., Van Gompel, J. J.
(2003). Multiple Determinants Contribute to the Virulence of HSV Ocular and CNS Infection and Identification of Serine 34 of the US1 Gene as an Ocular Disease Determinant. IOVS
44: 2657-2668
[Abstract]
[Full Text]
-
Moxley, M. J., Block, T. M., Liu, H.-C., Fraser, N. W., Perng, G.-C., Wechsler, S. L., Su, Y.-H.
(2002). Herpes simplex virus type 1 infection prevents detachment of nerve growth factor-differentiated PC12 cells in culture. J. Gen. Virol.
83: 1591-1600
[Abstract]
[Full Text]
-
Winkler, M. T., Schang, L. S., Doster, A., Holt, T., Jones, C.
(2000). Analysis of cyclins in trigeminal ganglia of calves infected with bovine herpesvirus-1. J. Gen. Virol.
81: 2993-2998
[Abstract]
[Full Text]
-
Derbigny, W. A., Kim, S. K., Caughman, G. B., O'Callaghan, D. J.
(2000). The EICP22 Protein of Equine Herpesvirus 1 Physically Interacts with the Immediate-Early Protein and with Itself To Form Dimers and Higher-Order Complexes. J. Virol.
74: 1425-1435
[Abstract]
[Full Text]
-
Advani, S. J., Brandimarti, R., Weichselbaum, R. R., Roizman, B.
(2000). The Disappearance of Cyclins A and B and the Increase in Activity of the G2/M-Phase Cellular Kinase cdc2 in Herpes Simplex Virus 1-Infected Cells Require Expression of the alpha 22/US1.5 and UL13 Viral Genes. J. Virol.
74: 8-15
[Abstract]
[Full Text]
-
Markovitz, N. S., Filatov, F., Roizman, B.
(1999). The UL3 Protein of Herpes Simplex Virus 1 Is Translated Predominantly from the Second In-Frame Methionine Codon and Is Subject to at Least Two Posttranslational Modifications. J. Virol.
73: 8010-8018
[Abstract]
[Full Text]
-
Hobbs, W. E. II, DeLuca, N. A.
(1999). Perturbation of Cell Cycle Progression and Cellular Gene Expression as a Function of Herpes Simplex Virus ICP0. J. Virol.
73: 8245-8255
[Abstract]
[Full Text]
-
Bruni, R., Fineschi, B., Ogle, W. O., Roizman, B.
(1999). A Novel Cellular Protein, p60, Interacting with both Herpes Simplex Virus 1 Regulatory Proteins ICP22 and ICP0 Is Modified in a Cell-Type-Specific Manner and Is Recruited to the Nucleus after Infection. J. Virol.
73: 3810-3817
[Abstract]
[Full Text]
-
Ogle, W. O., Roizman, B.
(1999). Functional Anatomy of Herpes Simplex Virus 1 Overlapping Genes Encoding Infected-Cell Protein 22 and US1.5 Protein. J. Virol.
73: 4305-4315
[Abstract]
[Full Text]